DEPDC1B and prostate cancer: It has been reported to be upregulated in oral carcinoma [39], non-small-cell lung carcinoma [40], soft tissue sarcoma [41], malignant melanoma, etc. Besides, elevated DEPDC1B is shown to suggest shorter biochemical relapse-free survival in prostate cancer patients [42].